Sector News

Derica Rice to retire as Lilly CFO

June 1, 2017
Life sciences

Eli Lilly and Company announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company. Rice is also a member of Lilly’s executive committee.

“On behalf of our shareholders, our board, our executive team and the company, I want to thank Derica for his leadership as our CFO over the past eleven years,” said David A. Ricks, Lilly’s chairman, president and chief executive officer. “Derica has been a core part of Lilly’s turnaround, our innovation strategy and our consistent ability to set and then meet targets and commitments. His personal integrity and commitment to our company has been unwavering.”

“Derica helped navigate the YZ period, served as a trusted advisor to three CEOs, left a lasting impact on Lilly talent across the globe and transformed our global services delivery organization,” said Ricks. “The entire Lilly family would like to thank Derica and wish him the very best in his next set of endeavors.”

Rice joined Lilly in 1990, holding numerous roles in finance and operations throughout his career. He was promoted to his current role in May 2006 after serving as Lilly’s vice president and controller. Rice also has served as Lilly’s general manager in the United Kingdom, executive director and chief financial officer of European operations and chief financial officer for the company’s operations in Canada. Rice earned his MBA from Indiana University and a bachelor’s degree in electrical engineering from the General Motors Institute.

“It’s been a true calling to work at Lilly, helping people live longer, healthier lives. I can’t think of a more noble pursuit than that,” said Rice. “It’s been a wonderful ride and I’m grateful for the opportunity.”

Lilly is considering internal and external candidates to succeed Rice.

Source: Eli Lilly and Company

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach